Although additional compliances for Trodelvy are underway, the company expects full approval in the U.S. sometime in the next quarter. According to the statement, Immunomedics would file for approvals with the European regulators in the first half of next year. "We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments," Gilead CEO Daniel O'Day said. Price Movement: Giliead stock cloesd 2.84% higher at $65.58 per share on Friday, however, it dropped by a marginal 0.12% during the after-market trading hours.